Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Proto Labs, Inc. (Protolabs) (NYSE: PRLB) provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Minnesota corporation with common stock listed on the New York Stock Exchange, Protolabs submits periodic and current reports that document its financial condition, operating results, and significant corporate events.
Investors researching PRLB can use this page to review annual reports on Form 10-K and quarterly reports on Form 10-Q, which present audited and interim financial statements, revenue by service line (Injection Molding, CNC Machining, 3D Printing, Sheet Metal, and Other Revenue), and discussions of non-GAAP measures such as adjusted EBITDA, non-GAAP gross margin, and non-GAAP net income. These filings explain how management evaluates performance and how digital factory and Protolabs Network fulfillment contribute to overall results.
The page also aggregates current reports on Form 8-K, which Protolabs uses to announce material events. Recent 8-K filings reference quarterly earnings press releases and leadership changes, including the appointment of a Chief Technology and AI Officer and related executive transitions. Such filings may also incorporate press releases as exhibits, giving readers direct access to management commentary and outlook statements.
Alongside these core reports, users can monitor exhibits related to executive compensation, inducement equity awards under NYSE Rule 303A.08, and severance arrangements referenced in executive agreements. Insider transaction reports on Form 4, proxy statements on Schedule 14A, and other ownership or governance-related filings, when available, help investors understand how executives and directors are compensated and how they hold or transact in PRLB shares.
Stock Titan enhances this information with AI-powered summaries that highlight key points in lengthy documents, such as revenue trends, margin drivers, and notable risk factors. Real-time updates from EDGAR ensure that new Protolabs filings, including 10-K, 10-Q, 8-K, and Form 4 reports, are quickly reflected, allowing users to review the underlying disclosures while relying on AI-generated explanations to interpret complex accounting and regulatory language.
Proto Labs Inc Chief Financial Officer Daniel Schumacher reported a Form 4 transaction involving company common stock. On February 13, 2026, he disposed of 1,267 shares of Proto Labs common stock at $67.52 per share to satisfy tax obligations by delivering shares. After this tax-withholding disposition, he directly owned 42,704 common shares of Proto Labs.
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported two transactions in company common stock. On February 17, 2026, he sold 5,000 shares in an open-market transaction at a weighted average price of $66.463 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 25,302 shares directly held afterward.
Earlier, on February 13, 2026, he disposed of 1,540 shares at $67.52 per share to cover tax obligations through a stock withholding transaction, after which his direct holdings were 30,302 shares. The open-market sale prices ranged from $66.01 to $66.87 per share.
Disciplined Growth Investors, Inc. filed an amended Schedule 13G reporting its ownership in Proto Labs Inc12/31/2025, it beneficially owned 2,673,729 shares of Proto Labs common stock, representing 11.3% of the class.
The firm has sole voting power over 2,398,250 shares and sole dispositive power over 2,673,729 shares, with no shared voting or dispositive power. It certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Proto Labs.
Proto Labs Chief Operations Officer Michael R. Kenison reported a tax-related share withholding transaction. On 02/10/2026, 2,684 shares of common stock were disposed of at $53.18 per share to cover tax obligations, leaving him with 31,842 shares of Proto Labs common stock held directly.
Proto Labs Inc. Chief Financial Officer Daniel Schumacher reported routine equity compensation activity. On February 11, 2026, he exercised 3,135 employee stock options at an exercise price of $33.84 per share, receiving the same number of common shares and holding 43,971 shares directly afterward.
On February 10, 2026, 6,809 common shares were withheld at $53.18 per share to satisfy the exercise price or tax liabilities related to equity awards. All transactions are reported as direct ownership, and the option was noted as fully vested.
Proto Labs Inc. executive stock sale disclosed
Proto Labs Inc. Chief Operations Officer Michael R. Kenison reported selling 2,500 shares of common stock on February 6, 2026 at $60 per share. After this planned trade, he beneficially owns 34,526 shares of Proto Labs common stock.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Mr. Kenison adopted on August 15, 2025, which is designed to allow insiders to sell shares according to predetermined instructions.
This notice states that an insider plans to sell 7,500 shares of common stock of the issuer under Rule 144. The planned sale, through Morgan Stanley Smith Barney, has an aggregate market value of $393,600 based on the filing and is expected around February 6, 2026 on the NYSE. The filing notes that there were 23,678,745 common shares outstanding at the time referenced.
The 7,500 shares to be sold were acquired as restricted stock units from the issuer on May 20, 2020. In the past three months, Rule 10b5-1 sales for Michael Kenison included a prior sale of 3,048 common shares on November 25, 2025 for gross proceeds of $152,930.66.
Proto Labs, Inc. filed an amended current report to correct a guidance figure in its previously issued outlook. The amendment clarifies that the company’s GAAP diluted earnings per share guidance range for the first quarter of 2026 is $0.18 to $0.26, instead of the $0.17 to $0.25 range originally described in the attached press release. No other aspects of the earlier report or the press release were changed, and the correction is described as a scrivener’s error.
Proto Labs, Inc. reported record fourth-quarter 2025 revenue of $136.5 million, up 12.1% from a year ago, and returned to profitability with net income of $6.0 million, or $0.25 per diluted share, versus a small loss last year. Non-GAAP net income was $10.7 million, or $0.44 per diluted share.
For full year 2025, revenue reached a record $533.1 million, a 6.4% increase, with net income rising to $21.2 million, or $0.88 per diluted share. CNC Machining led growth, while 3D Printing and Injection Molding declined slightly. Adjusted EBITDA was $78.1 million, a 14.7% margin, and operating cash flow was $74.5 million, supporting a year-end cash and investments balance of $142.4 million.
Management highlighted four strategic pillars—elevating customer experience, accelerating innovation, expanding production, and driving operational efficiency—and issued 2026 guidance calling for 6% to 8% revenue growth. For Q1 2026, the company expects revenue of $130.0 million to $138.0 million and diluted EPS of $0.17 to $0.25, or $0.36 to $0.44 on a non-GAAP basis.
Proto Labs, Inc. Chief Operations Officer Michael R. Kenison reported the acquisition of 8,128 shares of Proto Labs common stock on January 29, 2026, at a reported price of $0 per share. Following this transaction, he beneficially owns 37,026 shares of Proto Labs common stock in direct ownership, as disclosed in this Form 4 insider filing.